Chronic Myeloid Leukemia, Version 1.2019 Clinical Practice Guidelines in Oncology

被引：168

作者：

Radich, Jerald P. ^{[1
]}

Deininger, Michael ^{[2
]}

Abboud, Camille N. ^{[3
,4
]}

Altman, Jessica K. ^{[5
]}

Berman, Ellin ^{[6
]}

Bhatia, Ravi ^{[7
]}

Bhatnagar, Bhavana ^{[8
,9
]}

Curtin, Peter ^{[10
]}

DeAngelo, Daniel J. ^{[11
]}

Gotlib, Jason ^{[12
]}

Hobbs, Gabriela ^{[13
]}

Jagasia, Madan ^{[14
]}

Kantarjian, Hagop M. ^{[15
]}

Maness, Lori ^{[16
]}

Metheny, Leland ^{[17
,18
]}

Moore, Joseph O. ^{[19
]}

Pallera, Arnel ^{[20
]}

Pancari, Philip ^{[21
]}

Patnaik, Mrinal ^{[22
]}

Purev, Enkhtsetseg ^{[23
]}

Rose, Michal G. ^{[24
]}

Shah, Neil P. ^{[25
]}

Smith, B. Douglas ^{[26
]}

Snyder, David S. ^{[27
]}

Sweet, Kendra L. ^{[28
]}

Talpaz, Moshe ^{[29
]}

Thompson, James ^{[30
]}

Yang, David T. ^{[31
]}

Gregory, Kristina M.

Sundar, Hema

机构：

[1] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA 98109 USA

[2] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA

[3] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA

[4] Washington Univ, Sch Med, St Louis, MO USA

[5] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA

[6] Mem Sloan Kettering Canc Ctr, New York, NY USA

[7] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL USA

[8] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA

[9] Solove Res Inst, Columbus, OH USA

[10] UC San Diego Moores Canc Ctr, La Jolla, CA USA

[11] Dana Farber Brigham & Womens Canc Ctr, Milford, MA USA

[12] Stanford Canc Inst, Stanford, CA USA

[13] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA

[14] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[15] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[16] Fred & Pamela Buffett Canc Ctr, Omaha, NE USA

[17] Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA

[18] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA

[19] Duke Canc Inst, Durham, NC USA

[20] Univ Tennessee, Hlth Sci Ctr, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA

[21] Fox Chase Canc Ctr, Philadelphia, PA USA

[22] Mayo Clin, Ctr Canc, Phoenix, AZ USA

[23] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA

[24] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA

[25] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[26] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[27] City Hope Comprehens Canc Ctr, Duarte, CA USA

[28] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[29] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA

[30] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[31] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53706 USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2018年 / 16卷 / 09期

关键词：

CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE INHIBITORS; IN-SITU HYBRIDIZATION; SUBCUTANEOUS OMACETAXINE MEPESUCCINATE; CHROMOSOME-NEGATIVE METAPHASES; PATIENTS RECEIVING IMATINIB; CHRONIC-PHASE CML; CLONAL CYTOGENETIC ABNORMALITIES; PULMONARY ARTERIAL-HYPERTENSION; HARMONIZING CURRENT METHODOLOGY;

D O I：

10.6004/jnccn.2018.0071

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t(9; 22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor (TKI) therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML (CP-CML). The selection TKI therapy should be based on the risk score, toxicity profile of TKI, patient's age, ability to tolerate therapy, and the presence of comorbid conditions. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CP-CML.

引用

页码：1108 / 1135

页数：28

共 163 条

[11]

BIERNAUX C, 1995, BLOOD, V86, P3118

[12] The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease [J].

Bose, S ;

Deininger, M ;

Gora-Tybor, J ;

Goldman, JM ;

Melo, JV .

BLOOD, 1998, 92 (09) :3362-3367

[13] Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory [J].

Bouchet, Stephane ;

Titier, Karine ;

Moore, Nicholas ;

Lassalle, Regis ;

Ambrosino, Basmah ;

Poulette, Sylvie ;

Schuld, Peter ;

Belanger, Coralie ;

Mahon, Francois-Xavier ;

Molimard, Mathieu .

FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2013, 27 (06) :690-697

[14] Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia [J].

Branford, S. ;

Cross, N. C. P. ;

Hochhaus, A. ;

Radich, J. ;

Saglio, G. ;

Kaeda, J. ;

Goldman, J. ;

Hughes, T. .

LEUKEMIA, 2006, 20 (11) :1925-1930

[15] Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis [J].

Branford, S ;

Rudzki, Z ;

Walsh, S ;

Parkinson, I ;

Grigg, A ;

Szer, J ;

Taylor, K ;

Herrmann, R ;

Seymour, JF ;

Arthur, C ;

Joske, D ;

Lynch, K ;

Hughes, T .

BLOOD, 2003, 102 (01) :276-283

[16] Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations [J].

Branford, S ;

Rudzki, Z ;

Parkinson, I ;

Grigg, A ;

Taylor, K ;

Seymour, JF ;

Durrant, S ;

Browett, P ;

Schwarer, AP ;

Arthur, C ;

Catalano, J ;

Leahy, MF ;

Filshie, R ;

Bradstock, K ;

Herrmann, R ;

Joske, D ;

Lynch, K ;

Hughes, T .

BLOOD, 2004, 104 (09) :2926-2932

[17] Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials [J].

Branford, Susan ;

Fletcher, Linda ;

Cross, Nicholas C. P. ;

Mueller, Martin C. ;

Hochhaus, Andreas ;

Kim, Dong-Wook ;

Radich, Jerald P. ;

Saglio, Giuseppe ;

Pane, Fabrizio ;

Kamel-Reid, Suzanne ;

Wang, Y. Lynn ;

Press, Richard D. ;

Lynch, Kevin ;

Rudzki, Zbigniew ;

Goldman, John M. ;

Hughes, Timothy .

BLOOD, 2008, 112 (08) :3330-3338

[18] Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline [J].

Branford, Susan ;

Yeung, David T. ;

Parker, Wendy T. ;

Roberts, Nicola D. ;

Purins, Leanne ;

Braley, Jodi A. ;

Altamura, Haley K. ;

Yeoman, Alexandra L. ;

Georgievski, Jasmina ;

Jamison, Bronte A. ;

Phillis, Stuart ;

Donaldson, Zoe ;

Leong, Mary ;

Fletcher, Linda ;

Seymour, John F. ;

Grigg, Andrew P. ;

Ross, David M. ;

Hughes, Timothy P. .

BLOOD, 2014, 124 (04) :511-518

[19] Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority [J].

Bumm, T ;

Müller, C ;

Al-Ali, HK ;

Krohn, K ;

Shepherd, P ;

Schmidt, E ;

Leiblein, S ;

Franke, C ;

Hennig, E ;

Friedrich, T ;

Krahl, R ;

Niederwieser, D ;

Deininger, MWN .

BLOOD, 2003, 101 (05) :1941-1949

[20] Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group [J].

Cervantes, Francisco ;

Lopez-Garrido, Pilar ;

Montero, Maria-Isabel ;

Jonte, Fermin ;

Martinez, Jesus ;

Hernandez-Boluda, Juan-Carlos ;

Calbacho, Maria ;

Sureda, Anna ;

Perez-Rus, Gloria ;

Nieto, Jose B. ;

Perez-Lopez, Cristina ;

Roman-Gomez, Jose ;

Gonzalez, Marcos ;

Pereira, Arturo ;

Colomer, Dolors .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (08) :1317-1324

← 1 2 3 4 5 6 7 8 9 10 →